RIPE-KG · Version 1.1.0 · Resource
ripekg:work/10.1016%2Fs1473-3099%2823%2900199-8
https://w3id.org/ripe/ripe-kg/work/10.1016%2Fs1473-3099%2823%2900199-8
| Subject | Predicate | Object |
|---|---|---|
ripekg:work/10.1016%2Fj.nmni.2025.101692Homologous and heterologous booster of COVID-19 vaccines: A systematic review and meta-analysis |
http://purl.org/spar/cito/cites |
ripekg:work/10.1016%2Fs1473-3099%2823%2900199-8Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trial |
ripekg:work/10.1016%2Fs1473-3099%2823%2900199-8Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trial |
prism:doi |
10.1016/s1473-3099(23)00199-8 |
ripekg:work/10.1016%2Fs1473-3099%2823%2900199-8Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trial |
dcterms:title |
Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trial |
ripekg:work/10.1016%2Fs1473-3099%2823%2900199-8Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trial |
rdf:type |
node1 |
ripekg:work/10.1016%2Fs1473-3099%2823%2900199-8Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trial |
rdf:type |
http://purl.org/spar/fabio/Work |
ripekg:work/10.1016%2Fs1473-3099%2823%2900199-8Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trial |
rdf:type |
rdfs:Resource |
ripekg:work/10.1016%2Fs1473-3099%2823%2900199-8Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trial |
rdf:type |
owl:Thing |
ripekg:work/10.1016%2Fs1473-3099%2823%2900199-8Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trial |
rdf:type |
prov:Entity |
ripekg:work/10.1016%2Fs1473-3099%2823%2900199-8Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trial |
rdf:type |
ripe:WorkWork |
ripekg:work/10.1016%2Fs1473-3099%2823%2900199-8Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trial |
owl:sameAs |
https://semopenalex.org/work/W4377088821 |